Document is current
Any future updates will be listed below
-
Authors
Niekler, Patricia https://orcid.org/0000-0001-8916-8480
Goettler, David https://orcid.org/0000-0002-9224-0647
Liese, Johannes https://orcid.org/0000-0002-5569-4914
Streng, Andrea https://orcid.org/0000-0003-2377-7106
-
Funding
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA, Rixensart, Belgium (BoD RSV Study, PO 4450516642)
Universitätsklinikum Würzburg
- License Information
-
More Information
Article History
Received: 11 September 2025
Accepted: 10 December 2025
First Online: 16 December 2025
Declarations
:
: JL received research grants, and/or speaker’s fees, fees for participation in advisory board meetings from GlaxoSmithKline, Janssen-Cilag, Julius Clinical, Pfizer Pharma, Sanofi Pasteur/AstraZeneca, SPMSD, MSD, and Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit. AS received research grants, and/or speaker’s fees, fees for participation in advisory board meetings and travelling grants from GlaxoSmithKline, Pfizer Pharma, Janssen-Cilag, Julius Clinical, MSD, Sanofi Pasteur/AstraZeneca, and Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit. PN and DG declare that they have no competing interests.
: The Ethics Committee of the Faculty of Medicine at the University of Würzburg (Germany) approved the study (No. 20210720-01). All analyses were performed as remote data queries on fully anonymized data from the Federal Statistical Office. Subgroups with less than 3 persons were censored by the Federal Statistical Office for data protection reasons.
: Not applicable.
